Crescent Biopharma Inc(CBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CBIO Crescent Biopharma Inc

Closed 01-23 16:00:00 EST

12.80

-0.83

-6.09%

盘后12.80

+0.000.00%

16:10 EST

High13.97	Low12.31	Vol144.08K
Open13.63	D1 Closing13.63	Amplitude12.18%
Mkt Cap352.73M	Tradable Cap139.15M	Total Shares27.56M
T/O1.86M	T/O Rate1.33%	Tradable Shares10.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CBIO","market":"US","secType":"STK","nameCN":"Crescent Biopharma Inc","latestPrice":12.8,"timestamp":1769202000000,"preClose":13.63,"halted":0,"volume":144078,"hourTrading":{"tag":"盘后","latestPrice":12.8,"preClose":12.8,"latestTime":"16:10 EST","volume":288,"amount":3686.4,"timestamp":1769202604894,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.06089508437270726,"floatShares":10871000,"shares":27556800,"eps":-21.9706,"marketStatus":"Closed","change":-0.83,"latestTime":"01-23 16:00:00 EST","open":13.63,"high":13.97,"low":12.31,"amount":1857604.108456,"amplitude":0.12179,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-21.9706,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769418000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1389330000000,"exchange":"NASDAQ","adjPreClose":13.63,"preHourTrading":{"tag":"盘前","latestPrice":13.9674,"preClose":13.63,"latestTime":"09:07 EST","volume":350,"amount":4886.903,"timestamp":1769177259194,"change":0.3374,"changeRate":0.024754,"amplitude":0.024754},"postHourTrading":{"tag":"盘后","latestPrice":12.8,"preClose":12.8,"latestTime":"16:10 EST","volume":288,"amount":3686.4,"timestamp":1769202604894,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.702368,"impliedVol":2.2495,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/CBIO/wiki","defaultTab":"wiki","newsList":[{"id":"2605867214","title":"BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2605867214","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605867214?lang=en_us&edition=fundamental","pubTime":"2026-01-21 23:49","pubTimestamp":1769010597,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers CompaniesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL6N3YM11M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HAL","TDY","EXE","LUCD","NNE","BK4533","LXRX","BK4141","BKR","KHC","WMB","ALB","ALGS","GM","F","IE00B29SXL02.USD","LBRT","PLD","BIOA","LPTH","ROCK","BK4534","DXC","OCUL","LU2430703095.HKD","TFC","IE00BBT3K403.USD","SLB","TRV","OCGN","AVR","NATH","CNX","LSTA","CDE","JNJ","LNG","NEM","SCHW","HL","AMBQ","INTC","UAL","LU0985481810.HKD","LU0154245673.USD","CBIO","IE00B775SV38.USD"],"gpt_icon":1},{"id":"2605483858","title":"BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous","url":"https://stock-news.laohu8.com/highlight/detail?id=2605483858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605483858?lang=en_us&edition=fundamental","pubTime":"2026-01-21 22:25","pubTimestamp":1769005524,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s FamousEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL6N3YM0P9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HL","PAVM","RIO.UK","IE00BLSP4452.SGD","LU1023059063.AUD","CBIO","ARM","LU0417517546.SGD","PLD","NEM","IE0004091025.USD","NATH","LXRX","JNJ","LUCD","RIO.AU","LU1201861165.SGD","FCX","LPTH","TRV","LU2362540622.SGD","LBRT","AVR","LU0347712357.USD","TEL","SG9999002224.SGD","TFC","HAL","CDE","SG9999002232.USD","SLB","ROCK","NFLX","UAL","BK4145","LU1066051811.HKD","BIOA","LU2272731782.SGD","TDY","LU0130103400.USD","OCUL","LU0079474960.USD","KHC","LU2272731600.USD","SCHW","BHP.AU","ALB","LU2463526074.USD","BKR"],"gpt_icon":0},{"id":"2605610079","title":"This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2605610079","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605610079?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:49","pubTimestamp":1769003340,"startTime":"0","endTime":"0","summary":"Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.\nConsidering buying CBIO stock? Here’s what analysts think: \nPhoto via Shutterstock","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/21/Side-View-Of-Concentrated-Crypto-Trader-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/21/Side-View-Of-Concentrated-Crypto-Trader-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/26/01/50033906/this-crescent-biopharma-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/26/01/50033906/this-crescent-biopharma-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4112","CBIO"],"gpt_icon":0},{"id":"2605102397","title":"Crescent Biopharma Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2605102397","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605102397?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:51","pubTimestamp":1768999860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 21, 2026 07:51 ET (12:51 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"2605104388","title":"Guggenheim Initiates Crescent Biopharma at Buy With $35 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2605104388","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605104388?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:22","pubTimestamp":1768998134,"startTime":"0","endTime":"0","summary":"Crescent Biopharma (CBIO) has an average rating of buy and mean price target of $28.20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"2605109233","title":"BUZZ-Guggenheim initiates coverage on Crescent Biopharma with 'buy'","url":"https://stock-news.laohu8.com/highlight/detail?id=2605109233","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605109233?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:50","pubTimestamp":1768996221,"startTime":"0","endTime":"0","summary":"BUZZ-Guggenheim initiates coverage on Crescent Biopharma with 'buy'** Guggenheim starts coverage on drugmaker Crescent Biopharma CBIO.O with \"buy\"; sets PT at $35** Says CBIO has a compelling investment thesis as it awaits long-term data for its experimental lung cancer treatment, CR-001, in Q1 2027 ** Says this will provide a clear comparable to Summit's SMMT.O ivonescimab, which belongs to a similar class of drugs** CBIO's proprietary antibody-drug conjugate  pipeline, known as \"guided-missile\" cancer drugs, could generate independent value as monotherapy and be synergistic with CR-001 in earlier solid tumor treatment settings - Brokerage** \"We see CBIO as set up to be awarded significant value both from what the company is replicating and what the company is pioneering\" - Brokerage** As of last close, CBIO stock down 52.37% in the past 12 months ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL4N3YM0ZU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","SMMT","CBIO"],"gpt_icon":0},{"id":"2605109659","title":"Crescent Biopharma initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2605109659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605109659?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:35","pubTimestamp":1768995326,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Brad Canino initiated coverage of Crescent Biopharma (CBIO) with a Buy rating and $35 price target. Crescent is 12-15 months fro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crescent-biopharma-initiated-with-a-buy-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crescent-biopharma-initiated-with-a-buy-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2605510501","title":"Crescent Biopharma Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2605510501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605510501?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:09","pubTimestamp":1768993752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM0SV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"2604116540","title":"LifeSci Capital Reaffirms Their Buy Rating on Crescent Biopharma (CBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604116540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604116540?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:37","pubTimestamp":1768916270,"startTime":"0","endTime":"0","summary":"In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Crescent Biopharma, with a price target of $22.00. Accordin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-reaffirms-their-buy-rating-on-crescent-biopharma-cbio-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-reaffirms-their-buy-rating-on-crescent-biopharma-cbio-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CBIO"],"gpt_icon":0},{"id":"2601885723","title":"FDA Clears IND for Crescent Biopharma's CR-001 Targeting Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885723","media":"Reuters","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885723?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614420,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc. has announced regulatory clearance of its Investigational New Drug  applications for two cancer therapies: CR-001, a PD-1 x VEGF bispecific antibody, and CR-003, an ITGB6-targeted antibody drug-conjugate , both intended for the treatment of advanced solid tumors. The U.S. Food and Drug Administration  cleared the IND for CR-001, enabling Crescent to proceed with a Phase 1/2 global clinical trial expected to begin in the first quarter of 2026. Additionally, Crescent’s partner, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., received IND approval for CR-003  from the National Medical Products Administration  of China. The collaboration grants Crescent exclusive rights to develop and commercialize CR-003 outside Greater China, while Kelun-Biotech holds exclusive rights to CR-001 in Greater China. Four clinical trials across Crescent’s portfolio are planned to commence in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL8GXSFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","SG9999014013.SGD","BK4139","BK4112","NDAQ","SG9999014005.SGD","002422","LU2210149790.SGD","LU0196878994.USD","LU0314104364.USD","CBIO","LU2095319765.USD","SG9999014039.USD","06990","BK4585","BK4588","BK1161","IE00B3QW5Z07.USD","LU1064130708.USD","LU1934453819.USD","IE00BGHQF748.EUR","LU2210150020.SGD","LU2148510915.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU1979443071.USD","BK0239","SG9999014021.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2601885797","title":"Crescent Biopharma Announces Regulatory Clearances of Ind Applications for Cr-001, a Pd-1 X Vegf Bispecific Antibody and Cr-003, an Itgb6-Targeted ADC, for the Treatment of Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885797?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA5RWQ67:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2601885093","title":"Crescent Biopharma Inc - Four Clinical Trials Expected to Initiate in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885093?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA5RWQ67:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2601099885","title":"Crescent Biopharma Inc - Crescent Partner Kelun-Biotech Receives Ind Approval for Cr-003 (Skb105) by Nmpa of China","url":"https://stock-news.laohu8.com/highlight/detail?id=2601099885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601099885?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA5RWQ67:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2592118176","title":"Press Release: Crescent Biopharma Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2592118176","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592118176?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:15","pubTimestamp":1766092500,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Dec. 18, 2025  -- Crescent Biopharma, Inc.  , a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent directors on the Board of Directors approved the grant of options to purchase an aggregate of 129,626 shares of the Company's ordinary shares to three non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended . The options were approved on December 13, 2025, granted on December 15, 2025, and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2590366553","title":"Fairmount Funds Management LLC Reports Acquisition of Common Shares of Crescent Biopharma Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2590366553","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590366553?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:31","pubTimestamp":1765229466,"startTime":"0","endTime":"0","summary":"Fairmount Funds Management LLC, as a beneficial owner, reported the acquisition of common shares of Crescent Biopharma Inc. . The Form 4 was filed by more than one reporting person, including Fairmount Funds Management LLC and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL3N2nRS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Fairmount Funds Management LLC Reports Acquisition of Common Shares of Crescent Biopharma Inc","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"2589314834","title":"BUZZ-U.S. STOCKS ON THE MOVE-Raymond James, CAVA, Paramount Skydance","url":"https://stock-news.laohu8.com/highlight/detail?id=2589314834","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589314834?lang=en_us&edition=fundamental","pubTime":"2025-12-05 03:04","pubTimestamp":1764875069,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Raymond James, CAVA, Paramount SkydanceEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL6N3XA0L6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MA","IE0009356076.USD","FIVE","ARE","HL","RJF","CBIO","TOL","KR","AI","NI","AXGN","HYNE","XYZ","IE00BQXX3C00.GBP","FISV","SNCR","GEV","CDE","PSKY","LKQ","SCCO","MDU","LEN","LU0157215616.USD","ULS","GCO","LU0426412945.USD","BK4077","BBW","HRL","DG","FCX","CURV","LU0823434740.USD","GWRE","V","DCI","CAVA","CVX","BETA","PPG"],"gpt_icon":1},{"id":"2589836664","title":"What's Happening With Crescent Biopharma Stock Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2589836664","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589836664?lang=en_us&edition=fundamental","pubTime":"2025-12-05 00:29","pubTimestamp":1764865740,"startTime":"0","endTime":"0","summary":"Cresent Biopharma shares were trading higher Thursday but have since reversed and begun trading lower after the company announced a partnership with Sichuan Kelun-Biotech Biopharmaceutical.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/04/medical.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/04/medical.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49212844/whats-happening-with-crescent-biopharma-stock-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49212844/whats-happening-with-crescent-biopharma-stock-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","CBIO"],"gpt_icon":0},{"id":"2588560881","title":"Crescent Biopharma Shares Jump 18% Premarket After Cancer Drug Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2588560881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588560881?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:28","pubTimestamp":1764851313,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL4N3XA0W6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CBIO","BK4139"],"gpt_icon":0},{"id":"2588888137","title":"BUZZ-Crescent Biopharma jumps after cancer drug partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2588888137","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588888137?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:24","pubTimestamp":1764851056,"startTime":"0","endTime":"0","summary":"BUZZ-Crescent Biopharma jumps after cancer drug partnership ** Shares of drugmaker Crescent Biopharma CBIO.O rise 36.5% to $18.30 premarket ** Co says it has formed an exclusive partnership with China's Kelun-Biotech to develop and market new cancer treatments** Co is also raising $185 million from investors to fund clinical trials - CBIO** Says deal gives Kelun-Biotech rights to co's experimental drug CR-001 in Greater China** CBIO's CR-001 aims to boost immune response and block blood supply to tumors; SKB105 targets solid tumors, co says** Both firms plan to test drugs alone and in combination; human trials for 3 drugs set for 2026, co says** Up to last close, stock was down ~46% YTD   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL4N3XA0UJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IVX.AU","BK4139","BK7096","002422","BK7508","LU1064130708.USD","LU1934453819.USD","LU1979443071.USD","LU2148510915.USD","LU0196878994.USD","06990","LU1064131003.USD","BK0060","CBIO","BK0239","BK7509"],"gpt_icon":0},{"id":"2588886694","title":"Crescent Biopharma Raises $185 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2588886694","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588886694?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:37","pubTimestamp":1764848225,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc. has announced a private placement of approximately $185 million in securities to institutional and accredited investors. The offering, which is expected to close around December 8, 2025, was not registered under the Securities Act of 1933 and involves the sale of shares and pre-funded warrants. Investors participating in the placement include Forbion, Fairmount, Vestal Point Capital, BVF Partners, ADAR1, Balyasny Asset Management, and Venrock Healthcare Capital Partners. The company plans to use the proceeds to advance its clinical and preclinical programs and for general corporate purposes, with an expected cash runway into 2028. Jefferies, TD Cowen, Guggenheim Securities, Cantor, and Wedbush & Co. served as placement agents, and Piper Sandler acted as financial advisor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL2X3jBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","CBIO","PIPR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.glycomimetics.com","stockEarnings":[{"period":"1week","weight":0.0904},{"period":"1month","weight":0.1246},{"period":"3month","weight":0.0741},{"period":"6month","weight":0.0256},{"period":"1year","weight":-0.4696},{"period":"ytd","weight":0.1492}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0173},{"period":"6month","weight":0.0814},{"period":"1year","weight":0.1361},{"period":"ytd","weight":0.0104}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.029952},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.015525},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.053963},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.063712},{"month":5,"riseRate":0.5,"avgChangeRate":0.092337},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022838},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058163},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.053488},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.058271},{"month":10,"riseRate":0.5,"avgChangeRate":0.107936},{"month":11,"riseRate":0.75,"avgChangeRate":0.290074},{"month":12,"riseRate":0.25,"avgChangeRate":-0.030216}],"exchange":"NASDAQ","name":"Crescent Biopharma Inc","nameEN":"Crescent Biopharma Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Crescent Biopharma Inc(CBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Crescent Biopharma Inc(CBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Crescent Biopharma Inc,CBIO,Crescent Biopharma Inc股票,Crescent Biopharma Inc股票老虎,Crescent Biopharma Inc股票老虎国际,Crescent Biopharma Inc行情,Crescent Biopharma Inc股票行情,Crescent Biopharma Inc股价,Crescent Biopharma Inc股市,Crescent Biopharma Inc股票价格,Crescent Biopharma Inc股票交易,Crescent Biopharma Inc股票购买,Crescent Biopharma Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Crescent Biopharma Inc(CBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Crescent Biopharma Inc(CBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}